SNTI News and Press, Senti Biosciences Inc. From 10/31/23

– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio’s proprietary Gene Circuit platform – SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Senti B...

- Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies - - Abstracts include new preclinical data demonstrating ongoing progress from collaboration with BlueRock Therapeutics and new technology d...

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platfor...

2023-08-11 10:41:32 ET Senti Biosciences press release ( NASDAQ: SNTI ): Q2 GAAP EPS of -$0.42. Revenue of $0.93M (-31.1% Y/Y). For further details see: Senti Biosciences GAAP EPS of -$0.42, revenue of $0.93M

– GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 – – IND for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, on track for 2H 2023 – – Cash, cash equivalents, and sho...

– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies – – Transaction anticipated to extend Senti Bio’s cash runway into Q4 2024 –...

SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced multiple presentations highligh...

2023-05-10 13:23:53 ET Senti Biosciences press release ( NASDAQ: SNTI ): Q1 GAAP EPS of -$0.42 beats by $0.13 . Revenue of $1.29M beats by $0.29M . For further details see: Senti Biosciences GAAP EPS of -$0.42 beats by $0.13, revenue of $1.29M beats by $0...

– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating th...

- Four abstracts accepted show the potential of applying gene circuits in multiple cell and gene therapy modalities for neurology, ophthalmology, and oncology - - New preclinical data demonstrate ongoing progress from collaborations with BlueRock and Spark - SOUTH SAN FRANCISCO, C...